title: Frontotemporal dementia: clinical, neuroimaging, and molecular biological findings in 6 patients.
abstract: Establishing the diagnosis in patients with clinical signs and symptoms suggesting primary degenerative disease with marked frontal lobe involvement is difficult. Neuroimaging methods, in particular positron emission tomography (PET) with the tracer 18fluoro-2-deoxyglucose (FDG) and cerebrospinal fluid (CSF) examination of beta-amyloid and tau-protein levels may give additional information. We report five patients with clinical and radiological features of degenerative dementia with predominantly frontal involvement and one patient with primary progressive aphasia Diagnostic work-up included computed tomography (CT), magnetic resonance imaging (MRI), PET and tau-protein and beta-amyloid level determination in CSF. While neuropsychological performance varied among patients, CT and MRI demonstrated persistently frontal lobe involvement. PET revealed corresponding changes with frontal hypometabolism, but in addition, four patients (among them two with no corresponding temporal changes in CT or MRI) showed a decreased glucose uptake in the temporal cortices. CSF samples from five patients revealed elevated beta-amyloid 1-42 and tau levels in three and two patients, respectively. Reduced beta-amyloid 1-40 was found in two patients. We conclude that occurrence of clinical symptoms of frontotemporal dementia is accompanied by frontal hypometabolism regardless of additional clinical findings. The value of determination of beta-amyloid and tau protein levels remains to be determined.
authors.affiliation: Dept of Neurology, University of Giessen, Germany. marek.jauss@neuro.med.uni-giessen.de
authors.forename: M
authors.initials: M
authors.lastname: Jauss
authors.forename: K
authors.initials: K
authors.lastname: Herholz
authors.forename: L
authors.initials: L
authors.lastname: Kracht
authors.forename: J
authors.initials: J
authors.lastname: Pantel
authors.forename: T
authors.initials: T
authors.lastname: Hartmann
authors.forename: M
authors.initials: M
authors.lastname: Jensen
authors.forename: M
authors.initials: M
authors.lastname: Essig
authors.forename: J
authors.initials: J
authors.lastname: Schröder
mesh_terms: D000368:Aged; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid / Q000378:metabolism; D002556:Cerebrospinal Fluid Proteins / Q000378:metabolism; D003704:Dementia / Q000378:metabolism / Q000473:pathology* / Q000523:psychology*; D005260:Female; D005625:Frontal Lobe / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007206:Individuality; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid / Q000378:metabolism; D011569:Psychiatric Status Rating Scales; D013702:Temporal Lobe / Q000378:metabolism* / Q000473:pathology*; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D016875:tau Proteins / Q000134:cerebrospinal fluid / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D002556:Cerebrospinal Fluid Proteins; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); D016875:tau Proteins